Press Release No. 15
/ June 23, 2009 /
Berlin

Lack of “Happiness Hormone” Serotonin in the Brain Causes Impaired Maternal Behavior in Mice

A lack of serotonin, commonly known as the “happiness hormone”, in the brain slows the growth of mice after birth and is responsible for impaired maternal behavior later in life. This was the result of research conducted by Dr. Natalia Alenina, Dana Kikic, and Professor Michael Bader of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch, Germany. At the same time, the researchers discovered that the presence of serotonin in the brain is not crucial for the survival of the animals. Furthermore, they were able to confirm that there are two strictly separate pathways of serotonin production: One gene is responsible for the formation of serotonin in the brain, another gene for the production of the hormone in the body (PNAS, June 23, 2009, Vol. 106, No. 25, pp 10332-10337)*.

The researchers “switched off” the gene Tph2 in mice to elucidate the function of the gene in the brain. Tph2 produces the enzyme tryptophan hydroxylase (TPH), which is responsible for the formation of serotonin.

Mice lacking serotonin in the brain (below) are much smaller than normal mice (above). (Photo: Natalia Alenina/Copyright: MDC)

After the researchers switched off normal'>Tph2, the animals produced almost no serotonin in the brain. Nevertheless, the animals were viable and half of them survived until adulthood. However, they needed more sleep during the day and the regulation of their respiration, body temperature, and blood pressure was altered.

The female mice were able to give birth and produced enough milk to feed their pups, but their impaired maternal behavior led to poor survival of the offspring.

The Tph2 gene was discovered by MDC researchers several years ago together with researchers of the Free University (FU) Berlin and Humboldt University Berlin (HUB).

*Growth retardation and altered autonomic control in mice lacking brain serotonin

Natalia Alenina1*, Dana Kikic1*, Mihail Todiras1, Valentina Mosienko1, Fatimunnisa Qadri1, Ralph Plehm1, Philipp Boye1, Larissa Vilianovitch1, Reinhard Sohr2, Katja Tenner1, Heide Hörtnagl2, Michael Bader1
1Max-Delbrück-Center for Molecular Medicine (MDC), Robert-Rössle-Str. 10, D-13125 Berlin; 2Institute of Pharmacology, Charité-University Medicine, Berlin, Germany
*N.A. and D.K. contributed equally to this study.

Barbara Bachtler
Press and Public Affairs
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
Robert-Rössle-Straße 10
13125 Berlin, Germany
Phone: +49 (0) 30 94 06 - 38 96
Fax: +49 (0) 30 94 06 - 38 33
e-mail: presse@mdc-berlin.de
http://www.mdc-berlin.de/
 

Further information

Related news & events

Summit 24- Maike Sander
Press Release No. 30

Perspectives for the medicine of the future

What opportunities lie ahead for the future of medical research and healthcare? Scientists from the Helmholtz Association share their ideas with decision-makers from science, politics, patient organizations, biotech, and the pharmaceutical industry at the first Helmholtz Health Summit in Berlin.
Scientific image
© Felix Petermann, Max Delbrück Center
Press Release No. 29

Human and other primate hearts differ genetically

A team in the Hübner and Diecke Labs at the Max Delbrück Center have shown how human and non-human primate hearts differ genetically. The study, published in “Nature Cardiovascular Research,” reveals evolutionary adaptations in human hearts and provides new insights into cardiac disease.
Scientific image

Healthy organoids (left) show an organized neurogenic zone (shown in yellow) and neural progenitor cells (shown in red/pink). Huntington’s Disease organoids (right) exhibit almost no neural progenitors (red) and also show defects in cellular polarity (yellow). These defects have been described in the literature in human fetuses with Huntington’s disease.

© Selene Lickefett, Heinrich-Heine-Universität Düsseldorf, Werner Dykstra, Max Delbrück Center
Press Release No. 24

A new culprit in Huntington’s disease

Researchers in Berlin and Düsseldorf have implicated a new gene in the progression of Huntington’s disease in a brain organoid model. The gene may contribute to brain abnormalities much earlier than previously thought. The study was published in “Nature Communications.”
Wissenschaftliches Bild
© David Ausserhofer, Max Delbrück Center
Press Release No. 22

Sharpening the gene scissors together

The Max Delbrück Center, Berlin, and the biotech company AlgenScribe from Nice have agreed to cooperate to further develop their gene-editing tools. The aim is to utilize synergies, accelerate research, and ultimately develop cell therapies for genetically determined diseases.